|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation can be identified in about 45% of the patients with metastatic melanoma.
|
28162869 |
2017 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma.
|
28738051 |
2017 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma.
|
29552321 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAF<sup>V600E</sup> mutation in their tumors.
|
30765391 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK inhibitors have been shown to improve overall and progression-free survival among patients with metastatic melanoma.
|
31050693 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression.
|
31058079 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitors (BRAFi), in combination with MEK inhibitors, also resulted in improved overall survival compared with single-agent BRAFi in patients with <i>BRAFV600</i>-mutated metastatic melanoma.
|
31205512 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF- and MEK-targeted therapies are effective in BRAF V600E/K metastatic melanoma and lung cancers; however, responses are short-lived due to emergence of resistance.
|
31744895 |
2020 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 72-year-old male patient was receiving second-line chemotherapy for metastatic squamous cell carcinoma of the skin (SCCS) when he was diagnosed with concurrent metastatic melanoma (BRAF mutant).
|
27684455 |
2017 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 75-year-old male developed a swelling in his left inguinal region and was diagnosed with a metastatic melanoma, which was found to harbor a BRAF V600E mutation.
|
31260118 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 75-year-old woman was diagnosed with a BRAF V600E mutated metastatic melanoma.
|
25185693 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma.
|
27138260 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A combined therapy MEK inhibitor, Cobimetinib (CB) and BRAF inhibitor, Vemurafenib (VMF), results in an improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma.
|
28396940 |
2017 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
|
28719152 |
2017 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A patient with BRAF(L597S) mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor, TAK-733.
|
22798288 |
2012 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
|
24178368 |
2014 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
|
29721378 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib.
|
22332713 |
2012 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 100 patients with American Joint Committee on Cancer stage IIIC unresectable or stage IV melanoma and who underwent tumor DNA BRAF mutation testing were selected.
|
23026937 |
2013 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 48 patients (24 male, 24 female) with BRAF-mutated metastatic melanoma received dabrafenib and trametinib; median age was 48 years (range 23-75).
|
27470608 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.
|
20818844 |
2010 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
|
27336602 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A vemurafenib-resistant human metastatic melanoma cell line positive for the BRAF V600E mutation was established.
|
27354627 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, BRAF mutation determination is standard-of-care in metastatic melanoma, and a rapid, accurate assay is desirable.
|
31833840 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in the BRAF oncogene are observed in approximately 50% of cutaneous melanomas and the use of BRAF inhibitor (BRAFi) compounds has been reported to improve the outcome of patients with BRAF-mutated metastatic melanoma.
|
29956724 |
2018 |